Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Treatment can improve pugs’ PLE survival, study finds
Forty-three per cent of pugs died from causes presumed to be due to PLE.
Pugs with protein-losing enteropathy face early mortality rates.

A new study has explored how treatment can improve the short-term survival of pugs with protein-losing enteropathy (PLE).

Pugs with PLE have previously been linked with higher proportional mortality rates when compared to all other breeds in referral care.

In this latest study, from the Royal Veterinary College (RVC), researchers examined the clinical management and outcomes of 51 pugs diagnosed with PLE in UK primary care. The data was collected from the VetCompass programme.

Statistics reveal that 43 per cent of the pugs died presumed due to PLE, with over half of these deaths occurred within three months of the dog’s diagnosis. Sixty-four per cent of these pugs were euthanased, while the remainder had an unassisted death.

For most of the pugs in the study, the cause of their PLE diagnosis was unidentified.

Among the clinical signs for PLE were diarrhoea, vomiting, inappetence, lethargy, weight loss and increased drinking. At the time of death, other signs included pale mucous membranes, seizures and anaemia. 

Treatments for PLE are variable, and have included dietary therapy, prednisolone, clopidogrel, cyclosporin and cobalamin supplementation.

The pugs which were prescribed prednisolone or clopidogrel were most likely to be alive three months after their diagnosis. Researchers say this could mean that such treatments can improve pugs’ short-term outcomes.
However, the benefits of the treatments did not persist beyond one or two years after the diagnosis, meaning that further research would be needed for longer-term therapies.

The pugs which were diagnosed with PLE in primary care practice had similar outcomes to those in referral practices. Researchers suggest this could mean a poor prognosis regardless of treatment setting, although this could be due to more severe cases being referred to referral practices.

Aarti Kathrani, lead author of the study, said: “The results of our study will help to increase awareness and highlight the outcome and various causes of death in Pugs with protein-losing enteropathy.

“We hope the results will also help drive much-needed further research into the mechanism, pathophysiology and consequence of this disease, which is needed to help discover effective therapeutic targets that could help improve the prognosis of this guarded condition.”

The full study can be found in the Journal of Small Animal Practice.

Image © Shutterstock.com/New Africa

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.